There are many conditions, ranging from monogenic diseases to oncology, where the loss of protein function drives disease pathology. What if we could stabilise or modulate the function of these proteins to restore health? DUBTACs are an exciting new modality enabling drug discovery scientists to target previously undruggable pathways. Through the recruitment of a DUB enzyme to deubiquitinate a disease-linked protein, DUBTACs can achieve protein stabilisation or modulation of its function, leading to a therapeutic benefit. Our DUB-centric drug discovery platform is designed to support DUBTAC design and development. We can select the correct DUB partner for a given drug target, validate the chemically-induced proximity strategy through proof-of-principle studies, and build and characterise a library of novel DUBTACs. Learn more here ➡ https://rb.gy/payai #DrugDiscovery #DrugDevelopment #Research #Pharma #Biotech #DUBTAC #DUB
Ubiquigent Ltd
Biotechnology
Dundee, Scotland 1,128 followers
Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as powerful new therapeutics
About us
Ubiquigent enables the discovery and development of novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need. Founded 13 years ago, the Company has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system (UPS). As the partner chosen by many leading industry and academic organisations for their drug discovery programmes, Ubiquigent’s experience spans the development of DUB inhibitors and modulators in the fields of protein degradation, stabilisation, and homeostasis. Ubiquigent has an internal pipeline of drug discovery programmes and is developing a strong IP portfolio encompassing DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-Targeting Chimeras (DUBTACs) for partnering and commercialisation.
- Website
-
http://www.ubiquigent.com
External link for Ubiquigent Ltd
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Dundee, Scotland
- Type
- Privately Held
- Founded
- 2009
- Specialties
- Supplier of ubiquitin cascade products, kits and services, Featured product; E2scan and DUBscan kits, DUBprofiler: Determine your compound's DUB (deubiquitylase) inhibitory profile, and Ubiquitin cascade custom HTS assay development and reagent supply
Locations
-
Primary
Get directions
University Incubator, Dundee Technopole
James Lindsay Place
Dundee, Scotland DD1 5JJ, GB
Employees at Ubiquigent Ltd
Updates
-
Boutique Biotech...
PhD scientist pivoted to Head of Business Development @ Ubiquigent | Experiences in both biotech & CRO domains | Love a bit of SPR & Biacore | Chair of Governors at local primary school - doing my bit for the community
Ubiquigent Ltd is today celebrating its 15th anniversary! 🎉🎂🥳 During this time we have successfully supported over 120 different organisations ranging from large pharma such as Bristol Myers Squibb, Astellas Engineered Small Molecules U.K. Ltd. and Debiopharm, to smaller biotech and therapeutics companies including Mission Therapeutics and KSQ Therapeutics, Inc. and through to highly respected academic institutions in the development of novel DUB inhibitors, DUB-targeting PROTACs and DUBTACs. ✅ Delivered data on 500+ DUBprofiler projects, by screening thousands of compounds, several of which are now in the clinic (or close to). ✅ Supplied a further 200+ organisations with high quality & validated ubiquitin system research tools Not bad for a boutique biotech based in Dundee, Scotland. Well done to all the talented team involved at Ubiquigent, both present and past! We look forward to more collaborations with top pharma, biotechs and scientific institutions as we modulate the Deubiquitinase (DUB) enzymes for therapeutic and impactful outcomes to patients. #Deubiquitinase #Deubiquitinating #ubiquitin #DUBs #DUBTAC #drugdiscovery #biotech #research #drugdevelopment
-
-
📢 Promotional offer on ubiquitin research tools and reagents! To celebrate 15 years of supporting pharma, biotech, and academic partners with their ubiquitin-focused research, we are running a promotion on our full range of high-quality research reagents: ▪ Minimum discount of 15% on all orders ▪ Applicable to all Ubiquigent research tools ▪ Offer ends 31st August 2024 Find out how you can take advantage of this offer to drive your DUB-focused drug discovery: https://rb.gy/35clhh #DrugDiscovery #DrugDevelopment #Research
-
-
🔈 Published: structural basis for mechanism of action of clinical USP1 inhibitor, KSQ-4279! In collaboration with the University of Glasgow, we have successfully determined the cryo-EM structure and mode of binding of KSQ-4279 in the enzyme-substrate complex. The study revealed that KSQ-4279 and ML323, an early USP1 inhibitor tool compound, bind to the same cryptic site of USP1, but disrupt the protein structure in subtly different ways. These structural and mechanistic insights will inform the design of the next generation of USP1 inhibitors to overcome PARP inhibitor resistance in tumours. Find out more and read the pre-print paper here: https://rb.gy/1zrzt9 #DUB #Deubiquitinase #DrugDiscovery #USP1 #cryoEM #KSQ4279
-
A fantastic summary of active companies in the USP1 DUB space from our Head of BD, Hozefa Amijee!
PhD scientist pivoted to Head of Business Development @ Ubiquigent | Experiences in both biotech & CRO domains | Love a bit of SPR & Biacore | Chair of Governors at local primary school - doing my bit for the community
🎮 ℝ𝔼𝔸𝔻𝕐 ℙ𝕃𝔸𝕐𝔼ℝ 𝕆ℕ𝔼 {USP} 🎯 Targeting USP1 has become one of the hottest pursuits in the realm of cancer drug discovery, with numerous players revealing their strategies. From those already making strides in clinical trials to the others showcasing at this year's #AACR2024, the field is lively with activity around this specific DUB. And let's not forget many more with patents highlighting USP1 targeting IP. Check out the attached document for my comprehensive list of everyone (to my knowledge) participating in this game of DUB. And hey, if I’m allowed to say it, many of these organisations have tapped into Ubiquigent’s DUB-centric biology platform, gaining valuable insights and achieving the next level with their programs, along the way. A little shoutout to Debiopharm for showcasing DUBprofiler data at this year’s #AACR. Game On! #USP1 #DrugDiscovery #Biotech #oncology #DDR #DUBs p.s downloadable pdf has useful links to press releases, posters or published patents. or I can send this list directly if you let me know in the comments.
-
Great to take part in the Platforms for Drug Discovery and Development Spotlight session at #BioTrinity alongside other R&D companies developing innovative platform technologies!
This afternoon, we attended the Platforms for Drug Discovery and Development Spotlight. Platform technologies enable companies to develop new drug candidates more efficiently and, in this session, we heard from some of the most innovative companies in the space: ▪ Cyril GILBERT, Kimialys ▪ Jason Mundin, MBA, Ubiquigent Ltd ▪ Stephen Myatt, Macomics ▪ Dan Turner, ENHANC3D GENOMICS ▪ Richard Vellacott, BiologIC Technologies ▪ Hakim Yadi Ph.D. OBE, Closed Loop Medicine Thank you Dejan Brkic, Thermo Fisher Scientific, for chairing the session. #DrugDiscovery #Pharma #PlatformTechnologies #BioTrinity
-
-
Our team has arrived at #BioTrinity! We’re looking forward to an exciting programme of presentations from some of the UK’s most exciting life science companies, hearing about the latest innovations in oncology, rare diseases, neurodegenerative diseases, and more. 🔈 Be sure to catch Jason Mundin, MBA’s presentation in the Platforms for Drug Discovery and Development session tomorrow. Get in touch to learn more: https://rb.gy/an5d9u #DrugDiscovery #DrugDevelopment #DUBs #DUBTAC Hozefa Amijee
Ubiquigent - Contact us
ubiquigent.com
-
Next week our team are heading to London for OBN (UK) Ltd’s #BioTrinity, joining R&D companies, investors, and academics to explore how we can catalyse growth in the life sciences. Don’t miss CEO Jason Mundin, MBA’s presentation as part of the Platforms for Drug Discovery and Development spotlight, where he will be sharing updates on our DUB-centric platform and our pipeline of novel DUB modulators. Interested in learning more? Get in touch! 📧 info@ubiquigent.com Hozefa Amijee #DrugDiscovery #DrugDevelopment #Biotech #DUB #DUBTAC
-
-
Did you miss us at #BIOEuropeSpring? You can still arrange a meeting! The digital partnering event opens today, and our Head of Business Development, Hozefa Amijee, is ready to introduce you to our DUB-targeting approach ➡ https://rb.gy/l7o212 #Biotech #DrugDiscovery #DrugDevelopment #Pharma #DUBTAC #StrategicPartnerships
-
-
We are pleased to announce that we have entered an agreement with Debiopharm to support the development of Debiopharm’s USP1 inhibitor programme, Debio 0432. Under the agreement, we will deploy our DUB-focused platform to develop novel target engagement assays to support Debio 0432 as it approaches the clinic. 💬 Our CEO, Jason Mundin, says: “Following our successful collaborations with other clinical stage companies, this latest agreement further demonstrates the capability of Ubiquigent’s platform to address all aspects of DUB drug discovery and development, encompassing target validation, hit-to-lead, candidate selection, translational research, and the development of assays to support clinical evaluation. With multiple assets now reaching clinical stage, we look forward to seeing the continued progression and expansion of the DUB field over the coming years as more companies enter the space and new therapeutics enter the clinic.” Read the full press release: https://rb.gy/rrjzkn #DrugDiscovery #DUB #DrugDevelopment
Ubiquigent - Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
ubiquigent.com